BROOMFIELD — Alio Inc., a Broomfield-based medical-technology company, has added a veteran of the health care sector to its board of directors.
Jyoti Palaniappan joined Alio after decades of health care experience, including with Adaptive Biotechnologies, Bigfoot Biomedical, Abbott Laboratories, Thermo Fisher Scientific and McKinsey & Co.
He serves as chief commercial officer for Fabric Genomics Inc., an Oakland, California-based company democratizing genomic-driven precision medicine.
“We are pleased to have an innovative leader like Jyoti join our Board of Directors,” Dave Kuraguntla, Alio’s co-founder and CEO, said in a prepared statement. “He brings to Alio a wealth of knowledge not just about the ever-changing healthcare market but commercial strategy. His insights and expertise will help us continue to hone our product roadmap while reinforcing the infrastructure that will allow us to scale effectively.”
Alio Medical, a division of Alio Inc., develops SmartPatch technology to use artificial intelligence to monitor multiple chronic diseases, including end-stage renal disease patients undergoing hemodialysis.
“I’ve been fortunate to work with a number of start-ups throughout my career, both as an advisor and employee,” Palaniappan said in a statement. “The common theme with start-ups is significant focus on defining and driving mission to ultimately improving lives in a clinical and cost-effective manner. Working with Alio will allow me to lend my expertise to their journey of better serving those living with chronic conditions. I look forward to being part of that journey and helping them with their vision of what remote patient monitoring can look like.”Alio announced in June 2021 that it had raised $20 million in Series B round led by Thomas Krebs, former treasurer of Penumbra Inc., and by Zekavat Investment Group.